AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Keynote 355 os8/8/2023 If you remember, that’s a study of about 900 women with triple-negative breast cancer, or metastatic disease, or locally advanced unresectable, and it was a first-line trial for these patients. I was thinking back that it looks like we're right around probably the 1-year anniversary of when atezolizumab was FDA approved for this very indication based on IMpassion130. Tiffany, do you want to tell us a little bit about the IMpassion130 trial and what patients might benefit from atezolizumab? We were excited to see data from the IMpassion130 trial with a checkpoint inhibitor, atezolizumab, added to nab-paclitaxel, but this only benefits a relatively small group of patients in the metastatic triple-negative setting. We have such limited options, and we have a very clear idea of what the outcome is for the majority of patients. We've been hit by the poor options available to patients in the metastatic setting and for patients who don't have a great response in the early stage setting. Rugo, MD: With that general idea of trying to pick out treatments based on what type of disease somebody has, so HER2-low disease, how are we personalizing medication for patients? Of course 1 area where we really want to focus on personalizing medication-not that we don't want to do it for everybody-is triple-negative breast cancer. A review of the IMpassion130 trial data on atezolizumab for the treatment of triple-negative breast cancer and the impact on PFS and OS for patients with PD-L1+ tumors.
0 Comments
Read More
Leave a Reply. |